An international, multicenter study was conducted to assess the long-term safety and efficacy of an experimental monoclonal antibody against interleukin-13 in patients with eosinophilic esophagitis.
Surveillance recommendations are based on the initial grade of dysplasia.
Low expression of the HPV-related marker cyclin D1 appears to be an independent prognostic marker in Barrett high-grade dysplasia and esophageal adenocarcinoma.
Patients with Barrett’s esophagus undergoing endoscopic eradication therapy demonstrated a low rate of recurrence of intestinal metaplasia and dysplasia after complete eradication of intestinal metaplasia.
An abnormal glucose tolerance test to screen for potential dumping syndrome around 3 months of age should be considered in infants born with esophageal atresia.
An electronic nose that measures volatile organic compounds can detect Barrett esophagus.
Esophageal squamous cell carcinoma represents the predominant histologic type of esophageal cancer worldwide.
As a precursor to esophageal adenocarcinoma, Barrett esophagus is a crucial diagnosis for gastroenterologists to make during upper endoscopy.
A risk prediction model consisting of 8 independent diagnostics can provide potential insight into a patient’s risk for Barrett’s esophagus before endoscopy, according to a study in published in Lancet Digital Health.
Gastroenterologists who are members of an EoE consortia are much more likely to routinely screen for adrenal insufficiency in children with eosinophilic esophagitis who are being treated with topical corticosteroids.
